The new label expansion for Eli Lilly and Company/Boehringer Ingelheim GmbH’s SGLT2 inhibitor Jardiance (empagliflozin) for heart failure with preserved left ventricular ejection fraction (HFpEF) gives it a significant edge in the space given its superior efficacy and more clearly defined labeling compared with Novartis AG’s heart failure drug Entresto. However, the potential success of another competitor in the SGLT2 inhibitor class could make its reign short-lived.
Jardiance Gets Heart Failure Nod, But How Long Will Its Reign Last?
The SGLT2 inhibitor has better efficacy and clearer labeling than Novartis’s Entresto in heart failure with preserved ejection fraction, but AstraZeneca’s Farxiga is expected to produce Phase III data by June.
More from New Products
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
• By
The approval of another Novartis drug with a different mechanism means the company is further cornering multiple parts of IgAN pathogenesis.
• By
It might be the beginning of the end for the orphan drugs party but there is still sales growth enjoyment to be had for the sector, whose star performers are now looking increasingly like mainstream drugs.
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
More from Scrip
• By
By allowing it to enter the brain more easily, trontinemab’s brain shuttle brings more patients to ‘amyloid zero’ levels faster, and with fewer brain swelling side effects.
• By
Compass' bispecific antibody tovecimig hits primary efficacy endpoint in Phase II/III top-line data in advanced biliary tract cancer, and may have class side-effect advantages. But additional survival data may be needed to support US approval.
• By
AstraZeneca remains committed to investing in R&D and alliances in China, where Susan Galbraith, the UK major’s head of oncology R&D, sees innovation eventually reaching parity with the US and Europe.